Fundraising FoxInflammX Therapeutics
Tampa, US · Founded 2020 · Delaware corporation
Find your way into InflammX Therapeutics
64 people in our graph can introduce you to the InflammX Therapeutics team.
Sign up to see every warm intro you have to InflammX Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InflammX Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
InflammX Therapeutics develops Xiflam, a once-daily oral small molecule that inhibits the pathologically open Connexin43 hemichannel to modulate the NLRP3 inflammasome, targeting inflammation in retinal disease. Its lead indication is the dry form of age-related macular degeneration (dry AMD), for which there is currently no approved pharmacologic treatment.
Founders & leadership
BL
Brian LevyChief Executive Officer2020–2026Brian Levy is CEO of InflammX Therapeutics and Vitranu Inc., and previously held roles including Chief Medical Officer at Aerie Pharmaceuticals and Bausch & Lomb, where he led R&D and clinical development. He has extensive background in ophthalmology, including academic work at UCSF and private practice, and has contributed to regulatory filings for multiple ophthalmic pharmaceuticals and devices.
DP
David PoolNamed on SEC filing
RS
Rajiv ShuklaNamed on SEC filing
PR
Phil RosenfeldNamed on SEC filing
DB
David BoyerNamed on SEC filing
JB
James BlairNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$15.4M disclosed across 2 of 3 rounds · 2020–2022
▶Undisclosed amountofferedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason WernerDirector
- Phil RosenfeldDirector
- David BoyerDirector
- Rajiv ShuklaDirector
- Richard RubinoDirector
- James BlairDirector
- David PoolExecutive Officer
- Brian LevyExecutive Officer, Director
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$8.4MraisedNov 2021 · 6 investors · BiotechnologyRule 506(b)
▶$8.4MraisedNov 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James BlairDirector
- Brian LevyExecutive Officer, Director
- David BoyerDirector
- David PoolExecutive Officer
- Jason WernerDirector
- Rajiv ShuklaDirector
- Phil RosenfeldDirector
- Offering amount
- $8.4M
- Amount sold
- $8.4M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7MraisedJan 2021 · 4 investors · BiotechnologyRule 506(b)
▶$7MraisedJan 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian LevyExecutive Officer, Director
- David PoolExecutive Officer
- Rajiv ShuklaDirector
- Phil RosenfeldDirector
- David BoyerDirector
- James BlairDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Inflammasome TherapeuticsInflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.
Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Companies working in the same space as InflammX Therapeutics.
Frequently asked questions
- What does InflammX Therapeutics do?
- InflammX Therapeutics develops Xiflam, a once-daily oral small molecule that inhibits the pathologically open Connexin43 hemichannel to modulate the NLRP3 inflammasome, targeting inflammation in retinal disease. Its lead indication is the dry form of age-related macular degeneration (dry AMD), for which there is currently no approved pharmacologic treatment.
- How much funding has InflammX Therapeutics raised?
- InflammX Therapeutics has disclosed $15.4M raised across 2 of its 3 known rounds.
- Where is InflammX Therapeutics headquartered?
- InflammX Therapeutics is headquartered in Tampa, US.